FR2889532B1 - Anticorps diriges contre le recepteur du ldl - Google Patents

Anticorps diriges contre le recepteur du ldl

Info

Publication number
FR2889532B1
FR2889532B1 FR0508281A FR0508281A FR2889532B1 FR 2889532 B1 FR2889532 B1 FR 2889532B1 FR 0508281 A FR0508281 A FR 0508281A FR 0508281 A FR0508281 A FR 0508281A FR 2889532 B1 FR2889532 B1 FR 2889532B1
Authority
FR
France
Prior art keywords
antibodies against
ldl receptor
against ldl
receptor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0508281A
Other languages
English (en)
Other versions
FR2889532A1 (fr
Inventor
Christian Behrens
Christine Gaucher
Jean Francois Prost
Jamila Najib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR0508281A priority Critical patent/FR2889532B1/fr
Priority to PCT/FR2006/001807 priority patent/WO2007014992A2/fr
Priority to AU2006274752A priority patent/AU2006274752A1/en
Priority to CA002618050A priority patent/CA2618050A1/fr
Priority to JP2008524539A priority patent/JP2009502189A/ja
Priority to EP06794207A priority patent/EP1937722A2/fr
Publication of FR2889532A1 publication Critical patent/FR2889532A1/fr
Application granted granted Critical
Publication of FR2889532B1 publication Critical patent/FR2889532B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0508281A 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl Expired - Fee Related FR2889532B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0508281A FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl
PCT/FR2006/001807 WO2007014992A2 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
AU2006274752A AU2006274752A1 (en) 2005-08-03 2006-07-25 Antibodies directed against an LDL receptor
CA002618050A CA2618050A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl
JP2008524539A JP2009502189A (ja) 2005-08-03 2006-07-25 Ｌｄｌ受容体に対する抗体
EP06794207A EP1937722A2 (fr) 2005-08-03 2006-07-25 Anticorps dirigés contre le récepteur du ldl

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508281A FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl

Publications (2)

Publication Number Publication Date
FR2889532A1 FR2889532A1 (fr) 2007-02-09
FR2889532B1 true FR2889532B1 (fr) 2007-10-12

Family

ID=35883519

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0508281A Expired - Fee Related FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl

Country Status (6)

Country Link
EP (1) EP1937722A2 (fr)
JP (1) JP2009502189A (fr)
AU (1) AU2006274752A1 (fr)
CA (1) CA2618050A1 (fr)
FR (1) FR2889532B1 (fr)
WO (1) WO2007014992A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CA3128035A1 (fr) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Polytherapies pour l'administration dans l'ensemble de la barriere hemato-encephalique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
IL139217A0 (en) * 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
WO2002048388A2 (fr) * 2000-10-25 2002-06-20 Vincent Agnello Procede d'inhibition de l'infection au virus de l'hepatite c (vhc) et autres virus de la famille des flaviridae, et a tout autre virus formant dans le sang un complexe avec une lipoproteine de basse densite ou tres basse densite, par empechement de l'entree virale dans une cellule

Also Published As

Publication number Publication date
WO2007014992A2 (fr) 2007-02-08
AU2006274752A1 (en) 2007-02-08
WO2007014992A3 (fr) 2007-04-19
JP2009502189A (ja) 2009-01-29
EP1937722A2 (fr) 2008-07-02
FR2889532A1 (fr) 2007-02-09
CA2618050A1 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
ITBO20050495A1 (it) Elettrocatetere esogageo
DE602006003681D1 (de) Toner
DE602005014129D1 (de) Rohrleitung
DE602006020221D1 (de) Toner
DK2902690T3 (da) Anomalidetektor til rørledninger
ATE443753T1 (de) Nuancierungsmittel
DK1964852T3 (da) Anti-ilt7-antistof
NO20076607L (no) TWEAK - bindende antistoff
DK2081951T3 (da) Progesteron-receptorantagonister
DE502005007052D1 (de) Sitzbefestigungsvorrichtung
DK1925212T3 (da) Indkapslet snack
BRPI0715705A2 (pt) bateria
AT502862A3 (de) Verbindungsvorrichtung
FR2889533B1 (fr) Anticorps diriges contre le recepteur du ldl
DE602007000311D1 (de) Sitzstützstruktur
DE602007001626D1 (de) Schwingförderer
ITMI20061101A1 (it) Gattuccio
FR2889532B1 (fr) Anticorps diriges contre le recepteur du ldl
DE602006005138D1 (de) Nichtsteroide glucocorticoid-rezeptormodulatoren
FR2922212B1 (fr) Anticorps anti ricine
EP1936505A4 (fr) Dispositif de support de developpement de programme
DE602006001677D1 (de) Tonerverfahren
FR2887144B3 (fr) Audio vibromasseur
FR2910896B1 (fr) Anticorps monoclonal dirige contre le recepteur humain des ldl

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20140430